All Stories

  1. Drug-induced stress mediates Plasmodium falciparum ring-stage growth arrest and reduces in vitro parasite susceptibility to artemisinin
  2. Antimalarial drug discovery: progress and approaches
  3. Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment
  4. The RTS,S vaccine—a chance to regain the upper hand against malaria?
  5. Comparative Analysis of Plasmodium falciparum Genotyping via SNP Detection, Microsatellite Profiling, and Whole-Genome Sequencing
  6. The Plasmodium falciparum protein PfMRP1 functions as an influx ABC transporter
  7. Malaria parasite beats the heat
  8. Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials
  9. Hemozoin Promotes Lung Inflammation via Host Epithelial Activation
  10. Plasmodium berghei K13 Mutations Mediate In Vivo Artemisinin Resistance That Is Reversed by Proteasome Inhibition
  11. Genetic screens reveal a central role for heme metabolism in artemisinin susceptibility
  12. Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13
  13. Turning the tide: targeting PfCRT to combat drug-resistant P. falciparum?
  14. Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway
  15. A phase 1, placebo controlled, randomised, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics and antimalarial activity of the Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048
  16. Structure-Based Screening of Plasmodium berghei Glutathione S-Transferase Identifies CB-27 as a Novel Antiplasmodial Compound
  17. Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials
  18. Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
  19. The Antimalarial Natural Product Salinipostin A Identifies Essential α/β Serine Hydrolases Involved in Lipid Metabolism in P. falciparum Parasites
  20. Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery
  21. Structure and drug resistance of the Plasmodium falciparum transporter PfCRT
  22. Plasmodium falciparum resistance to piperaquine driven by PfCRT
  23. Blocking Plasmodium Development in Mosquitoes: A Powerful New Approach for Expanding Malaria Control Efforts
  24. Generation of Transmission-Competent Human Malaria Parasites with Chromosomally-Integrated Fluorescent Reporters
  25. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia
  26. Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum
  27. Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors
  28. Pyronaridine-artesunate Shows Promise as an Effective and Well-tolerated Treatment for Artemisinin-resistant Plasmodium falciparum Malaria
  29. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents
  30. Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone
  31. Global Spread of Mutant PfCRT and Its Pleiotropic Impact on Plasmodium falciparum Multidrug Resistance and Fitness
  32. Comparative 3D genome organization in apicomplexan parasites
  33. Plasmodium falciparum In Vitro Drug Resistance Selections and Gene Editing
  34. Open-source discovery of chemical leads for next-generation chemoprotective antimalarials
  35. Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model
  36. Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265
  37. Erratum for Brunschwig et al., “UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria”
  38. Evidence for Regulation of Hemoglobin Metabolism and Intracellular Ionic Flux by the Plasmodium falciparum Chloroquine Resistance Transporter
  39. Stable Integration and Comparison of hGrx1-roGFP2 and sfroGFP2 Redox Probes in the Malaria Parasite Plasmodium falciparum
  40. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine
  41. Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors
  42. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
  43. UCT943, a Next-GenerationPlasmodium falciparumPI4K Inhibitor Preclinical Candidate for the Treatment of Malaria
  44. Changes in genome organization of parasite-specific gene families during the Plasmodium transmission stages
  45. A Breathprint for Malaria: New Opportunities for Noninterventional Diagnostics and Mosquito Traps?
  46. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
  47. Hydrogen peroxide dynamics in subcellular compartments of malaria parasites using genetically encoded redox probes
  48. Protein Degradation Systems as Antimalarial Therapeutic Targets
  49. Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity
  50. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic
  51. Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity
  52. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
  53. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
  54. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites
  55. A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
  56. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
  57. Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro
  58. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue
  59. A high susceptibility to redox imbalance of the transmissible stages ofPlasmodium falciparumrevealed with a luciferase-based mature gametocyte assay
  60. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study
  61. Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology
  62. Drug discovery: Chemical diversity targets malaria
  63. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling
  64. UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes
  65. Artemisinin Action and Resistance in Plasmodium falciparum
  66. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
  67. A Worldwide Map ofPlasmodium falciparumK13-Propeller Polymorphisms
  68. A broad analysis of resistance development in the malaria parasite
  69. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
  70. CRISPR-Cas9-modifiedpfmdr1protectsPlasmodium falciparumasexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs
  71. Evidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria Parasites
  72. Substrate and Inhibitor Specificity of the Plasmodium berghei Equilibrative Nucleoside Transporter Type 1
  73. Combinatorial Genetic Modeling ofpfcrt-Mediated Drug Resistance Evolution inPlasmodium falciparum
  74. Luciferase-Based, High-Throughput Assay for Screening and Profiling Transmission-Blocking Compounds against Plasmodium falciparum Gametocytes
  75. Genome-wide transcriptome profiling reveals functional networks involving the Plasmodium falciparum drug resistance transporters PfCRT and PfMDR1
  76. Correction for Jiménez-Díaz et al., (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
  77. Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite’s food vacuole and alter drug sensitivities
  78. Profiling the Essential Nature of Lipid Metabolism in Asexual Blood and Gametocyte Stages of Plasmodium falciparum
  79. Adaptive evolution of malaria parasites in French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in pfcrt
  80. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
  81. Parasite-induced ER stress response in hepatocytes facilitates Plasmodium liver stage infection
  82. A novel multiple-stage antimalarial agent that inhibits protein synthesis
  83. Balancing drug resistance and growth rates via compensatory mutations in thePlasmodium falciparumchloroquine resistance transporter
  84. Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance
  85. Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate
  86. The Mu Subunit of Plasmodium falciparum Clathrin-Associated Adaptor Protein 2 ModulatesIn VitroParasite Response to Artemisinin and Quinine
  87. Yeast-Based High-Throughput Screen Identifies Plasmodium falciparum Equilibrative Nucleoside Transporter 1 Inhibitors That Kill Malaria Parasites
  88. Subtle Changes in Endochin-Like Quinolone Structure Alter the Site of Inhibition within the Cytochromebc1Complex of Plasmodium falciparum
  89. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates
  90. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
  91. DNA Repair Mechanisms and Their Biological Roles in the Malaria Parasite Plasmodium falciparum
  92. Multicolor Bioluminescence Boosts Malaria Research: Quantitative Dual-Color Assay and Single-Cell Imaging in Plasmodium falciparum Parasites
  93. N -Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds
  94. CRISPR-mediated genome editing of Plasmodium falciparum malaria parasites
  95. Supergenomic Network Compression and the Discovery of EXP1 as a Glutathione Transferase Inhibited by Artesunate
  96. Editing thePlasmodium vivaxGenome, Using Zinc-Finger Nucleases
  97. KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
  98. Transfusion of stored blood impairs host defenses against Gram‐negative pathogens in mice
  99. Mechanisms of Antimalarial Drug Action and Resistance
  100. Origin of Robustness in Generating Drug-Resistant Malaria Parasites
  101. Modeling Within-Host Effects of Drugs on Plasmodium falciparum Transmission and Prospects for Malaria Elimination
  102. Quinine Dimers Are Potent Inhibitors of the Plasmodium falciparum Chloroquine Resistance Transporter and Are Active against Quinoline-Resistant P. falciparum
  103. Discrimination of Potent Inhibitors ofToxoplasma gondiiEnoyl-Acyl Carrier Protein Reductase by a Thermal Shift Assay
  104. Characterization of the ATG8-conjugation system in 2Plasmodiumspecies with special focus on the liver stage
  105. Type II Fatty Acid Biosynthesis Is Essential for Plasmodium falciparum Sporozoite Development in the Midgut of Anopheles Mosquitoes
  106. Targeting Plasmodium PI(4)K to eliminate malaria
  107. Evidence for Pyronaridine as a Highly Effective Partner Drug for Treatment of Artemisinin-Resistant Malaria in a Rodent Model
  108. Plasmodium falciparum phosphoethanolamine methyltransferase is essential for malaria transmission
  109. Identification of MMV Malaria Box Inhibitors of Plasmodium falciparum Early-Stage Gametocytes Using a Luciferase-Based High-Throughput Assay
  110. Using Genetic Methods To Define the Targets of Compounds with Antimalarial Activity
  111. Eliminating Malaria
  112. UV-triggered Affinity Capture Identifies Interactions between thePlasmodium falciparumMultidrug Resistance Protein 1 (PfMDR1) and Antimalarial Agents in Live Parasitized Cells
  113. Malaria's Missing Number: Calculating the Human Component of R0 by a Within-Host Mechanistic Model of Plasmodium falciparum Infection and Transmission
  114. A key role for lipoic acid synthesis duringPlasmodiumliver stage development
  115. Spatial and temporal mapping of the PfEMP1 export pathway inPlasmodium falciparum
  116. Mitotic Evolution of Plasmodium falciparum Shows a Stable Core Genome but Recombination in Antigen Families
  117. Novel diaryl ureas with efficacy in a mouse model of malaria
  118. An integrated strategy for efficient vector construction and multi-gene expression in Plasmodium falciparum
  119. Degrees of chloroquine resistance in Plasmodium – Is the redox system involved?
  120. PfCRT and its role in antimalarial drug resistance
  121. Tricks in Plasmodium’s molecular repertoire – Escaping 3′UTR excision-based conditional silencing of the chloroquine resistance transporter gene
  122. Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases
  123. No Evidence of Decreased Artemisinin Efficacy in a High-Transmission Malaria Setting in Mali
  124. Loss of malarial susceptibility to artemisinin in Thailand
  125. Perspectives: The missing pieces
  126. Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria
  127. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum
  128. Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
  129. In VitroandIn VivoActivity of Solithromycin (CEM-101) against Plasmodium Species
  130. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue
  131. In vitro and in vivo activity of frenolicin B against Plasmodium falciparum and P berghei
  132. Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets
  133. Identifying apicoplast‐targeting antimalarials using high‐throughput compatible approaches
  134. Piperaquine Resistance Is Associated with a Copy Number Variation on Chromosome 5 in Drug-PressuredPlasmodium falciparumParasites
  135. Taking Charge: Feeding Malaria via Anion Channels
  136. In VivoandIn VitroAntimalarial Properties of Azithromycin-Chloroquine Combinations That Include the Resistance Reversal Agent Amlodipine
  137. Differential Drug Efflux or Accumulation Does Not Explain Variation in the Chloroquine Response of Plasmodium falciparum Strains Expressing the Same Isoform of Mutant PfCRT
  138. Evidence That Mutant PfCRT Facilitates the Transmission to Mosquitoes of Chloroquine-Treated Plasmodium Gametocytes
  139. Triclosan is minimally effective in rodent malaria models
  140. Molecular Markers of Plasmodium Resistance to Antimalarials
  141. How can we identify parasite genes that underlie antimalarial drug resistance?
  142. Spiroindolones, a Potent Compound Class for the Treatment of Malaria
  143. Investigations into the Role of the Plasmodium falciparum SERCA (PfATP6) L263E Mutation in Artemisinin Action and Resistance
  144. Identification of a Mutant PfCRT-Mediated Chloroquine Tolerance Phenotype in Plasmodium falciparum
  145. Priming the antimalarial pipeline
  146. Identification of a role for the PfEMP1 semi-conserved head structure in protein trafficking to the surface of Plasmodium falciparum infected red blood cells
  147. Recent insights into fatty acid acquisition and metabolism in malarial parasites
  148. A Method for Rapid Genetic Integration into Plasmodium falciparum Utilizing Mycobacteriophage Bxb1 Integrase
  149. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria
  150. A var gene promoter implicated in severe malaria nucleates silencing and is regulated by 3′ untranslated region and intronic cis-elements
  151. Role of Plasmodium falciparum Digestive Vacuole Plasmepsins in the Specificity and Antimalarial Mode of Action of Cysteine and Aspartic Protease Inhibitors
  152. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum
  153. Oleic Acid Biosynthesis in Plasmodium falciparum: Characterization of the Stearoyl-CoA Desaturase and Investigation as a Potential Therapeutic Target
  154. The Longin Domain Regulates the Steady-State Dynamics of Sec22 in Plasmodium falciparum
  155. Probing the multifactorial basis of Plasmodium falciparum quinine resistance: Evidence for a strain-specific contribution of the sodium-proton exchanger PfNHE
  156. In Vivo Selection ofPlasmodium falciparumParasites Carrying the Chloroquine-SusceptiblepfcrtK76 Allele after Treatment with Artemether-Lumefantrine in Africa
  157. Select pyrimidinones inhibit the propagation of the malarial parasite, Plasmodium falciparum
  158. Chemical genomics identifies compounds affecting Xenopus laevis pigment cell development
  159. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum
  160. Recent highlights in antimalarial drug resistance and chemotherapy research
  161. The Fatty Acid Biosynthesis Enzyme FabI Plays a Key Role in the Development of Liver-Stage Malarial Parasites
  162. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes
  163. Plasmodium falciparum Sec24 marks transitional ER that exports a model cargo via a diacidic motif
  164. Malaria: progress, perils, and prospects for eradication
  165. Arresting malaria parasite egress from infected red blood cells
  166. Characterization of a PRL protein tyrosine phosphatase from Plasmodium falciparum☆
  167. Advances in understanding the genetic basis of antimalarial drug resistance
  168. Discovery of novel inhibitors targeting enoyl–acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening
  169. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites
  170. X-ray Structural Analysis ofPlasmodium falciparumEnoyl Acyl Carrier Protein Reductase as a Pathway toward the Optimization of Triclosan Antimalarial Efficacy
  171. Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum
  172. Effects on growth, hemoglobin metabolism and paralogous gene expression resulting from disruption of genes encoding the digestive vacuole plasmepsins of Plasmodium falciparum
  173. Chloroquine-resistant isoforms of the Plasmodium falciparum chloroquine resistance transporter acidify lysosomal pH in HEK293 cells more than chloroquine-sensitive isoforms
  174. In Vitro Efficacy, Resistance Selection, and Structural Modeling Studies Implicate the Malarial Parasite Apicoplast as the Target of Azithromycin
  175. Transporters involved in resistance to antimalarial drugs
  176. PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX
  177. First evidence of pfcrt mutant Plasmodium falciparum in Madagascar
  178. Erratum: Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase
  179. Decreasing pfmdr1 Copy Number in Plasmodium falciparum Malaria Heightens Susceptibility to Mefloquine, Lumefantrine, Halofantrine, Quinine, and Artemisinin
  180. A ubiquitous Plasmodium protein displays a unique surface labeling pattern in sporozoites☆
  181. Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase
  182. Erratum to “Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4′-Substituted triclosan derivatives” [Bioorg. Med. Chem. Lett. 15 (2005) 5247–5252]
  183. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum
  184. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2′-Substituted triclosan derivatives
  185. Correction
  186. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4′-Substituted triclosan derivatives
  187. Disruption of a Plasmodium falciparum gene linked to male sexual development causes early arrest in gametocytogenesis
  188. Mutations Conferring Drug Resistance in Malaria Parasite Drug Transporters Pgh1 and PfCRT Do Not Affect Steady-State Vacuolar Ca2+
  189. Crystal structure analysis of plasmodium falciparum enoyl-acyl-carrier-protein reductase with nadh
  190. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum
  191. Evidence for apfcrt-Associated Chloroquine Efflux System in the Human Malarial ParasitePlasmodium falciparum
  192. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance
  193. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance
  194. Genetic Disruption of the Plasmodium falciparum Digestive Vacuole Plasmepsins Demonstrates Their Functional Redundancy
  195. Evidence for a Central Role for PfCRT in Conferring Plasmodium falciparum Resistance to Diverse Antimalarial Agents
  196. Drug resistance-associated pfCRT mutations confer decreased Plasmodium falciparum digestive vacuolar pH
  197. Chloroquine Resistance Modulated in Vitro by Expression Levels of the Plasmodium falciparum Chloroquine Resistance Transporter
  198. Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase
  200. Chloroquine Resistance inPlasmodium falciparumMalaria Parasites Conferred bypfcrtMutations
  201. Structural Elucidation of the Specificity of the Antibacterial Agent Triclosan for Malarial Enoyl Acyl Carrier Protein Reductase
  202. Alternative Mutations at Position 76 of the Vacuolar Transmembrane Protein PfCRT Are Associated with Chloroquine Resistance and Unique Stereospecific Quinine and Quinidine Responses inPlasmodium falciparum
  203. Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America
  204. Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum
  205. Disruption of Plasmodium falciparumChitinase Markedly Impairs Parasite Invasion of Mosquito Midgut
  206. Evidence for Different Mechanisms of Chloroquine Resistance in 2PlasmodiumSpecies That Cause Human Malaria
  207. Stage-dependent Localization of a Novel Gene Product of the Malaria Parasite,Plasmodium falciparum
  208. A Molecular Marker for Chloroquine-Resistant Falciparum Malaria
  209. Mutations in the P. falciparum Digestive Vacuole Transmembrane Protein PfCRT and Evidence for Their Role in Chloroquine Resistance
  210. Disruption of the C-terminal region of EBA-175 in the Dd2/Nm clone of Plasmodium falciparum does not affect erythrocyte invasion
  211. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum
  212. Plasmodium falciparum: Generation of a cDNA Library Enriched in Sporozoite-Specific Transcripts by Directional Tag Subtractive Hybridization
  213. Developmental arrest of the human malaria parasite Plasmodium falciparum within the mosquito midgut via CTRP gene disruption
  214. The selectable marker human dihydrofolate reductase enables sequential genetic manipulation of the Plasmodium berghei genome
  215. The chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferences
  216. The Anopheles Mosquito: Genomics and Transformation
  217. Genome projects, genetic analysis, and the changing landscape of malaria research
  218. Vesicular ATPase-overexpressing Cells Determine the Distribution of Malaria Parasite Oocysts on the Midguts of Mosquitoes
  219. A candidate molecule for chloroquine resistance in Plasmodium falciparum malaria
  220. P. falciparum CG2, Linked to Chloroquine Resistance, Does Not Resemble Na+/H+ Exchangers
  221. Plasmodium falciparum:Ribosomal P2 Protein Gene Expression Is Independent of the Developmentally Regulated rRNAs
  222. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen
  223. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil
  224. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria
  225. Conservation of the Plasmodium falciparum sporozoite surface protein gene, STARP, in field isolates and distinct species of Plasmodium
  226. Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP
  227. Nucleotide sequence of the F41 fimbriae subunit gene inEscherichia coliB41
  228. Construction of Plasmodium falciparumλ cDNA Libraries
  229. Mechanisms of Quinoline Resistance
  230. Production of Stage-Specific Plasmodium falciparum cDNA Libraries Using Subtractive Hybridization